No annual revenue total was found in IMMIX BIOPHARMA, INC.'s SEC filings.
Immix Biopharma, Inc. (IMMX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$24.7 million. As of Jun 30, 2026 it held $234.2 million in cash and investments and $1.0 million in total debt.
Revenue
—
Net income (TTM)
$-39.88M
-72.4% vs year-ago TTM
Operating cash flow (TTM)
$-38.50M
-207.8% vs year-ago TTM
Free cash flow (TTM)
$-39.09M
-190.0% vs year-ago TTM
EPS (TTM)
$-0.84
-7.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
52.96M
+91.1% vs prior year
Net cash
$233.16M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1873835
- Former names
- Immix Biopharma, Inc. (until Oct 27, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$1.4M |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$24.4M |
| Diluted EPS | -$0.89 | -$0.76 | -$0.89 | — |
| Operating cash flow | -$23.9M | -$14.6M | -$11.4M | -$1.6M |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | -$1.6M |
| Total assets | $104.8M | $22.9M | $19.9M | $18.2M |
| Total liabilities | $11.0M | $9.7M | $3.7M | $202,039 |
| Stockholders' equity | $93.8M | $13.3M | $16.2M | — |
| Cash and investments | $100.4M | $17.7M | $17.5M | $17.6M |
| Total debt | $1.1M | $1.1M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 22, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
All 244 Immix Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.